Navigation Links
Clinical trial to test stem cell approach for children with brain injury

A unique clinical trial will gauge the safety and potential of treating children suffering traumatic brain injury with stem cells derived from their own bone marrow starting early next year at The University of Texas Medical School at Houston and Memorial Hermann Children's Hospital.

The clinical trial is the first to apply stem cells to treat traumatic brain injury. It does not involve embryonic stem cells.

"There is no reparative treatment for traumatic brain injury," said principal investigator Charles Cox, M.D., The Children's Fund, Inc. Distinguished Professor in Pediatric Surgery and Trauma at the medical school. "All we can do now is try to prevent secondary damage by relieving pressure on the brain caused by the initial injury."

Unlike bone, muscle and other organs, the brain does not repair itself effectively. Traumatic brain injury victims can regain some function through rehabilitation. Studies show between 15 and 25 percent of children suffering severe traumatic brain injury die, and survivors of even moderate injury often are devastated for life.

Approved by the U.S. Food and Drug Administration and the university's Committee for the Protection of Human Subjects (CPHS), the clinical trial builds on laboratory and animal research indicating that bone-marrow derived stem cells can migrate to an injured area of the brain, differentiate into new neurons and support cells, and induce brain repair.

"This would be an absolutely novel treatment, the first ever with potential to repair a traumatically damaged brain," said James Baumgartner, M.D., associate professor of pediatric neurosurgery and co-principal investigator on the project.

As a Phase I clinical trial, the project's first emphasis is to establish the safety of the procedure, with a secondary goal of observing possible therapeutic effects.

Cox and Baumgartner have permission to recruit 10 head injury patients to the study between th e ages of 5 and 14 who meet criteria set for enrollment. After initial treatment and evaluation, a pediatric surgeon will approach the injured child's parents to explain the trial and request permission to enroll the child in the study.

If permission is granted, bone marrow will be extracted from the child's hip and then processed to derive two types of progenitor stem cells: mesenchymal stem cells, which differentiate into bone, cartilage and fat cells, and research indicates can also differentiate into neurons; and hematopoietic stem cells, which form all the cells needed for blood.

Preclinical research indicates that the mesenchymal stem cells play the major role in producing new neurons and support cells.

The Center for Cell and Gene Therapy at Baylor College of Medicine will process the bone marrow into the stem cell preparation and return it to Memorial Hermann Children's Hospital, where it will be given intravenously to the injured child.

All of this will be accomplished within 48 hours of the injury, Cox said. The children will be carefully monitored throughout for possible side effects. They will be evaluated for brain function one month and six months after the procedure to see if it is improved compared with historical data on the brain function of children of similar age who suffered a similar injury.

Safety trials involve too few patients to draw broad conclusions about the effectiveness of treatment. But they can set the stage for larger-scale research.

"All the preclinical data suggest this is a safe procedure with substantial information suggesting a possible treatment effect," Cox said.

Because the children are receiving their own cells, an immunological response to the treatment is unlikely.

Even marginal improvement could mean a great deal to someone who suffers a brain injury. "It could be the difference between being able to recognize your loved ones and not being able t o, or between doing things for yourself or having to rely on others. That would be a huge impact on families and on society," Cox said.

Trauma is far and away the main cause of death and disability among children, and the main reason children die from trauma is brain injury, Cox said.

The proposal was under review for a year. The U.S. Food and Drug Administration approved Cox's Investigational New Drug (IND) application in September. The UT-Houston CPHS, the university's institutional review board for research projects, approved the project in November and will continue to monitor it.

The project is funded by the Memorial Hermann Foundation, internal research funds from The Office of the President at The University of Texas Health Science Center at Houston, and the National Institute of Child Health and Development and the National Heart, Lung, and Blood Institute of the National Institutes of Health.


'"/>

Source:University of Texas Health Science Center at Houston


Related biology news :

1. International trial of two microbicides begins
2. Use of PET can reduce, may eliminate more strenuous drug development trials with animals
3. HIV vaccine trial breaks ground for future research
4. Roche clinical trial registry and results database launched
5. NIAID begins clinical trial of West Nile virus vaccine
6. Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT
7. Compound might defeat African sleeping sickness, clinical trial beginning this month
8. Why were the HIV prevention trials in commercial sex workers abandoned?
9. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
10. Industrial contaminants spread by seabirds in High Arctic, new Canadian study shows
11. Results of worlds first gene therapy trial for arthritis show approach safe, feasible
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):
(Date:5/24/2016)... ... May 24, 2016 , ... Media Cybernetics, ... new Media Cybernetics corporate branding reflects a results-driven revitalization for a company with ... The re-branding components include a crisp, refreshed logo and a new web presence. ...
(Date:5/23/2016)... WARSAW, Ind. , May 23, 2016 Zimmer ... in musculoskeletal healthcare, today announced that its Board of Directors ... stockholders for the second quarter of 2016. ... on or about July 29, 2016 to stockholders of record ... Future declarations of dividends are subject to approval of the ...
(Date:5/23/2016)... ... May 23, 2016 , ... RoviSys, a leading independent provider ... Ohio, has broken ground on a new building in Holly Springs, NC. With ... new location solidifies a commitment to business in the region. The new facility ...
(Date:5/20/2016)... Diego, CA (PRWEB) , ... May 20, 2016 , ... ... that 10 of its most experienced veterinary clients have treated over 100 of their ... cutting edge technology to provide the highest level of care for their patients. ...
Breaking Biology Technology: